NCT00500149 - A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD) | Biotech Hunter

Enrollment

129

Participants

Timeline

Start Date

June 13, 2007

Primary Completion Date

December 5, 2007

Study Completion Date

December 5, 2007

Conditions

ADHD

Interventions

DRUG

Vyvanse (lisdexamfetamine dimesylate)

Following completion of the open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day).

DRUG

Placebo

Trial Locations (9)

Unknown

Clinical Study Centers, LLC, Little Rock

Univ. of CA, Irvine Child Development Center, Irvine

Shire Clinical Research Site, Wildomar

Vince and Associates Clinical Research, Overland Park

Center for Psychiatry & Behavioral Medicine Inc, Las Vegas

Duke Child & Family Study Center, Durham

Duke University Medical Center, Durham

Shire Clinical Research Site, Houston

Shire Clinical Research Site, Lubbock